News


Calyxt Reports Fourth Quarter 2022 Financial Results and Provides Corporate Update

Calyxt Reports Fourth Quarter 2022 Financial Results and Provides Corporate Update

—Announced proposed merger with Cibus Global and filed initial registration statement on Form S-4— —Current customer projects under development are...
Read More
Calyxt, Inc. Announces its Filing of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLC

Calyxt, Inc. Announces its Filing of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLC

Roseville, MN and SAN DIEGO– February 15, 2023 – Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus,...
Read More
Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company

Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company

– The merger will bring together the technology platforms and facilities of two pioneering companies to create a leader in...
Read More
Calyxt Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

Calyxt Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

ROSEVILLE, Minn., Nov. 18, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company announced today that it has successfully completed...
Read More
Calyxt Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Calyxt Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

ROSEVILLE, Minn., Nov. 17, 2022 /PRNewswire/ -- Calyxt, Inc (Nasdaq: CLXT) a plant-based synthetic biology focused on engineering sustainable ingredients for customers...
Read More
Next »
« Previous